Consensus

← vista completa

Published on January 1, 2010 | http://doi.org/10.5867/medwave.2010.01.4337

Pathology diagnosis in breast cancer: update based on literature review

Revisión de la literatura sobre actualizaciones en diagnóstico patológico en cáncer de mama

Leonor Moyano, Laura Carreño, Valeria Cornejo, Arturo Espinoza, Pablo Matamala, Valeria Sanhueza

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Leonor Moyano

Sociedad Chilena de Mastología

Laura Carreño

Sociedad Chilena de Mastología

Valeria Cornejo

Sociedad Chilena de Mastología

Arturo Espinoza

Sociedad Chilena de Mastología

Pablo Matamala

Sociedad Chilena de Mastología

Valeria Sanhueza

Sociedad Chilena de Mastología

Figures

Article has no figures.

Forum

No messages

History

Citation Moyano L, Carreño L, Cornejo V, Espinoza A, Matamala P, Sanhueza V. Pathology diagnosis in breast cancer: update based on literature review. Medwave 2010;10(1):e4337 doi: 10.5867/medwave.2010.01.4337

Submission date 13/08/2009

Acceptance date 26/08/2009

Publication date 01/01/2010

Index

Metrics

Not available at the moment.

Notes

Keywords

diagnóstico patológico, cáncer de mama

Origin and peer review

sin revisión por pares

References

  1. Ali R, Hanly AM, Naughton P, Castineira CF, Landers R, Cahill RA, et al. Intraoperative frozen section assessment of sentinel lymph nodes in the operative management of women with symptomatic breast cancer. World J Surg Oncol. 2008 Jun 26;6:69. | CrossRef | PubMed
  2. Amin B, Hoda S, et al. "Isolated Tumor Cells/pN0(I+)" Category of Sentinel Lymph Node Staging Represents a Wider Range of Tumor Involvement Than That Implied by the Term "Isolated". 2007.
  3. Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher DW. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer. 2002 Mar 1;94(5):1383-90. | CrossRef | PubMed
  4. Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001 Aug;25(8):1054-60. | CrossRef | PubMed
  5. Ben-David MA, Kleer CG, Paramagul C, Griffith KA, Pierce LJ. Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis. Cancer. 2006 Jan 1;106(1):28-34. | CrossRef | PubMed
  6. Bethwaite P, Smith N, Delahunt B, Kenwright D. Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. J Clin Pathol. 1998 Jun;51(6):450-4. | CrossRef | PubMed
  7. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001 Apr 15;19(8):2263-71. | PubMed
  8. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 1;107(7):1440-7. | CrossRef | PubMed
  9. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000 Oct 15;18(20):3480-6. | PubMed
  10. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006 May;19(5):617-21. | CrossRef | PubMed
  11. Chapman JA, Miller NA, Lickley HL, Qian J, Christens-Barry WA, Fu Y, et al. Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment. BMC Cancer. 2007 Sep 10;7:174. | CrossRef | PubMed
  12. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol. 2005 May;18(5):615-20. | CrossRef | PubMed
  13. Creager AJ, Geisinger KR, Shiver SA, Perrier ND, Shen P, Ann Shaw J, et al. Intraoperative evaluation of sentinel lymph nodes for metastatic breast carcinoma by imprint cytology. Mod Pathol. 2002 Nov;15(11):1140-7. | CrossRef | PubMed
  14. Cserni G. Surgical pathological staging of breast cancer by sentinel lymph node biopsy with special emphasis on the histological work-up of axillary sentinel lymph nodes. Breast Cancer. 2004;11(3):242-9; discussion 264-6. | PubMed
  15. Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol. 2004 Jul;57(7):695-701. | CrossRef | PubMed
  16. Dabbs DJ, Johnson R. The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J. 2004 May-Jun;10(3):186-9. | CrossRef | PubMed
  17. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006 Nov;19(11):1506-11. Epub 2006 Aug 25. | PubMed
  18. Dadmanesh F, Fan X, Dastane A, Amin MB, Bose S. Comparative analysis of size estimation by mapping and counting number of blocks with ductal carcinoma in situ in breast excision specimens. Arch Pathol Lab Med. 2009 Jan;133(1):26-30. | PubMed
  19. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009 Aug 13;361(7):653-63. | CrossRef | PubMed
  20. Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008 Jun;109(3):405-16. Epub 2007 Aug 9. | CrossRef | PubMed
  21. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol. 2007 May;20(5):584-91. Epub 2007 Mar 30. | CrossRef | PubMed
  22. Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7(1):R93-100. Epub 2004 Nov 19. | CrossRef | PubMed
  23. Espinoza A, Gallegos M. Anatomia Patologica. En: Cancer de Mama. Sociedad Chilena de Anatomía Patológica.
  24. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995 Mar 15;75(6):1310-9. | CrossRef | PubMed
  25. Gilleard O, Goodman A, Cooper M, Davies M, Dunn J. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol. 2008 Jun 18;6:61 | CrossRef | PubMed
  26. Grin A, Horne G, Ennis M, O'Malley FP. Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods. Arch Pathol Lab Med. 2009 Jan;133(1):31-7. | PubMed
  27. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25. Epub 2006 May 31. | CrossRef | PubMed
  28. Harris EE, Solin LJ. The Diagnosis and Treatment of Ductal Carcinoma In Situ of the Breast. Breast J. 2000 Mar;6(2):78-95. | CrossRef | PubMed
  29. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20;25(33):5287-312. Epub 2007 Oct 22. | CrossRef | PubMed
  30. Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005 Oct;18(10):1305-20. | CrossRef | PubMed
  31. Jacobs TW. Recently Recognized Variants of Lobular Carcinoma In Situ (LCIS) With an Emphasis on Management of LCIS on Core Needle Biopsy. Pathology Case Review. 2003; 8(5): 211-19.
  32. Jacobs TW, Connolly JL, Schnitt SJ. Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol. 2002 Sep;26(9):1095-110. | CrossRef | PubMed
  33. Jeruss JS, Hunt KK, Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, et al. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective? Cancer. 2006 Nov 15;107(10):2328-36. | CrossRef | PubMed
  34. Jirström K, Ringberg A, Fernö M, Anagnostaki L, Landberg G. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer. 2003 Nov 17;89(10):1920-6. | CrossRef | PubMed
  35. Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009 Oct 20;27(30):4939-47. Epub 2009 Aug 31. | CrossRef | PubMed
  36. Kister SJ, Sommers SC, Haagensen CD, Cooley E. Re-evaluation of blood-vessel invasion as a prognostic factor in carcinoma of the breast. Cancer. 1966 Sep;19(9):1213-6. | CrossRef | PubMed
  37. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10;27(2):279-88. Epub 2008 Dec 8. | CrossRef | PubMed
  38. Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer. 2003 Nov 15;98(10):2105-13. | CrossRef | PubMed
  39. Lester SC, Connolly JL, Amin MB. College of American Pathologists protocol for the reporting of ductal carcinoma in situ. Arch Pathol Lab Med. 2009 Jan;133(1):13-4. | PubMed
  40. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009 Jan;133(1):15-25. | PubMed
  41. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 Feb;19(2):264-71. | CrossRef | PubMed
  42. Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol. 2006 Feb;19(2):195-207. | CrossRef | PubMed
  43. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007 Mar 15;109(6):1011-8. | CrossRef | PubMed
  44. MacAusland SG, Hepel JT, Chong FK, Galper SL, Gass JS, Ruthazer R, et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer. 2007 Dec 15;110(12):2648-53. | CrossRef | PubMed
  45. Mariuzzi L, Mombello A, Granchelli G, Rucco V, Tarocco E, Frank D, et al. Quantitative study of breast cancer progression: different pathways for various in situ cancers. Mod Pathol. 2002 Jan;15(1):18-25. | CrossRef | PubMed
  46. Martin RF. Surgical Clinics of North America. Surg Clin N Am 2007; 87.
  47. Menon S, Porter GJ, Evans AJ, Ellis IO, Elston CW, Hodi Z, et al. The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch. 2008 May;452(5):473-9. | CrossRef | PubMed
  48. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000 Dec 1;89(11):2187-94. | CrossRef | PubMed
  49. National Breast and Ovarian Cancer Centre (NBOCC). Recommendations for use of Sentinel node biopsy in early (operable) breast cancer. 2008 Jun. | Link
  50. NHS Cancer Screening Programmes. Pathology reporting of breast disease. NHSBSP Publication. Jan 2005 ; (58). | Link
  51. Farshid G, Downey P. Combined use of imaging and cytologic grading schemes for screen-detected breast abnormalities improves overall diagnostic accuracy. Cancer. 2005 Oct 25;105(5):282-8. | CrossRef | PubMed
  52. O'Malley FP, Mohsin SK, Badve S, Bose S, Collins LC, Ennis M, et al. Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. Mod Pathol. 2006 Feb;19(2):172-9. | CrossRef | PubMed
  53. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract. 2007 Jul;3(4):182-6. | CrossRef | PubMed
  54. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26. Epub 2004 Dec 10. | CrossRef | PubMed
  55. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. | CrossRef | PubMed
  56. Rashtian A, Iganej S, Amy Liu IL, Natarajan S. Close or positive margins after mastectomy for DCIS: pattern of relapse and potential indications for radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1016-20. | CrossRef | PubMed
  57. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000 Aug;13(8):866-73. | CrossRef | PubMed
  58. Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer. 2007 Jan;43(2):291-8. Epub 2006 Nov 21. | CrossRef | PubMed
  59. Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer. 1991 Mar 15;67(6):1498-503. | CrossRef | PubMed
  60. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008 May;13(5):477-93. | CrossRef | PubMed
  61. Schnitt SJ, Harris JR. Evolution of breast-conserving therapy for localized breast cancer. J Clin Oncol. 2008 Mar 20;26(9):1395-6. | CrossRef | PubMed
  62. Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J. 2003 Sep-Oct;9(5):374-9. | CrossRef | PubMed
  63. Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004 Oct;122(4):517-23. | CrossRef | PubMed
  64. Sigal-Zafrani B, Lewis JS, Clough KB, Vincent-Salomon A, Fourquet A, Meunier M, et al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications. Mod Pathol. 2004 Jan;17(1):81-8. | CrossRef | PubMed
  65. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998 Jun 15;82(12):2382-90. | CrossRef | PubMed
  66. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum Pathol. 1998 Oct;29(10):1056-62. | PubMed
  67. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. | CrossRef | PubMed
  68. Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol. 2008 Mar;15(3):863-71. Epub 2007 Nov 28. | CrossRef | PubMed
  69. Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer. 1990 Feb 1;65(3):518-29. | CrossRef | PubMed
  70. Tew K, Irwig L, Matthews A, Crowe P, Macaskill P. Meta-analysis of sentinel node imprint cytology in breast cancer. Br J Surg. 2005 Sep;92(9):1068-80. | CrossRef | PubMed
  71. Usami S, Moriya T, Amari M, Suzuki A, Ishida T, Sasano H, et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol. 2007 Apr;37(4):250-5. Epub 2007 May 7. | CrossRef | PubMed
  72. Weaver DL. Pathological evaluation of sentinel lymph nodes in breast cancer: a practical academic perspective from America. Histopathology. 2005 Jun;46(6):702-6. | CrossRef | PubMed
  73. Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol. 2003 Jan;27(1):82-90. | CrossRef | PubMed
  74. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11. | CrossRef | PubMed
  75. Zagouri F, Sergentanis TN, Zografos GC. Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol. 2007 May 31;5:57. | CrossRef | PubMed
  76. Zavagno G, Carcoforo P, Marconato R, Franchini Z, Scalco G, Burelli P, et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer. 2005 Mar 11;5:28. | CrossRef | PubMed
  77. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol. 2003 Mar;27(3):365-71. | CrossRef | PubMed